Patient experiences of weight loss with weight loss medication

  • Research type

    Research Study

  • Full title

    From prescription to perspectives: an interpretative phenomenological analysis to understand patient experiences of weight loss with GlP-1 or GLP-1/GIP medication

  • IRAS ID

    356310

  • Contact name

    Jade Sampford

  • Contact email

    jade.sampford2@nhs.net

  • Sponsor organisation

    Anglia Ruskin University

  • Duration of Study in the UK

    0 years, 9 months, 15 days

  • Research summary

    This research aims to explore the experiences of people taking medication to help with weight loss, specifically a type of weight loss treatment commonly known as Wegovy (GLP-1) or Mounjaro (GLP-1/GIP). These medications have recently become more common in the treatment of obesity. They work by mimicking a naturally occurring hormone in the body that helps regulate appetite.

    Clinical trials have shown that these medications can lead to significant weight loss and health improvements. However, in real-life settings, the results may vary. Some people may not lose as much weight as expected or may experience side effects that affect their ability to continue the treatment. This study aims to understand how people make sense of their weight loss experience using these medications, including any physical, emotional or psychological challenges.

    The research will involve interviews with up to 10 adult patients from the NHS who are being treated with Weogovy or Mounjaro for obesity. The participants will have been using these medications for between 12 and 24 months. Weight loss trajectory stabilises at around 12 months, providing a sufficient time-frame for individuals to have experienced weight loss with these medications.

    The study will use a qualitative approach called Interpretative Phenomenological Analysis (IPA), which focuses on gaining an in depth understanding of participants interpretations of their personal experiences.

    This research is important because patient experiences can influence treatment outcomes and satisfaction levels. Findings from this study can help to improve support for people taking these medications and inform NHS staff to provide more personalised care.

    I am a Clinical Specialist Physiotherapist and I will be conducting the study as part of my Professional Doctorate in Health and Social Care at Anglia Ruskin University. Recruitment will take place within the NHS weight management service in London where I work.

  • REC name

    London - Surrey Borders Research Ethics Committee

  • REC reference

    25/PR/1531

  • Date of REC Opinion

    17 Dec 2025

  • REC opinion

    Further Information Favourable Opinion